Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aß40 and Aß42 Peptides in Plasma
Pérez-Grijalba, V. ; Fandos, N. ; Canudas, J. ; Insua, D. ; Casabona, D. ; Lacosta, A.M. ; Montañés, M. ; Pesini, P. ; Sarasa, M. (Universidad de Zaragoza)
Resumen: Recent advances in neuroimaging and cerebrospinal fluid (CSF) biomarker assays have provided evidence of a long preclinical stage of Alzheimer''s disease (AD). This period is being increasingly targeted for secondary prevention trials of new therapies. In this context, the interest of a noninvasive, cost-effective amyloid-ß (Aß) blood-based test does not need to be overstated. Nevertheless, a thorough validation of these bioanalytical methods should be performed as a prerequisite for confident interpretation of clinical results. The aim of this study was to validate ELISA sandwich colorimetric ABtest40 and ABtest42 for the quantification of Aß40 and Aß42 in human plasma. The validation parameters assessed included precision, accuracy, sensitivity, specificity, recovery, and dilution linearity. ABtest40 and ABtest42 proved to be specific for their target peptide using Aß peptides with sequence similar to the target. Mean relative error in the quantification was found to be below 7.5 for both assays, with high intra-assay, inter-assay, and inter-batch precision (CV <9.0 on average). Sensitivity was assessed by determination of the limit of quantification fulfilling precision and accuracy criteria; it was established at 7.60 pg/ml and 3.60 pg/ml for ABtest40 and ABtest42, respectively. Plasma dilution linearity was demonstrated in PBS; however, dilution in a proprietary formulated buffer significantly increased the recovery of both Aß40 and Aß42 masked by matrix interactions, allowing a more comprehensive assessment of the free and total peptide levels in the plasma. In conclusion, both assays were successfully validated as tools for the quantification Aß40 and Aß42 in plasma.
Idioma: Inglés
DOI: 10.3233/JAD-160325
Año: 2016
Publicado en: JOURNAL OF ALZHEIMERS DISEASE 54, 2 (2016), 751-762
ISSN: 1387-2877
Factor impacto JCR: 3.731 (2016)
Categ. JCR: NEUROSCIENCES rank: 77 / 258 = 0.298 (2016) - Q2 - T1
Factor impacto SCIMAGO: 1.584 - Clinical Psychology (Q1) - Geriatrics and Gerontology (Q1) - Psychiatry and Mental Health (Q1) - Medicine (miscellaneous) (Q1) - Neuroscience (miscellaneous) (Q2)
Tipo y forma: Article (Published version)
Área (Departamento): Área Anatom.Anatom.Patológ.Com (Dpto. Anatom.,Embri.Genét.Ani.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2020-02-21-13:46:49)
Visitas y descargas
Idioma: Inglés
DOI: 10.3233/JAD-160325
Año: 2016
Publicado en: JOURNAL OF ALZHEIMERS DISEASE 54, 2 (2016), 751-762
ISSN: 1387-2877
Factor impacto JCR: 3.731 (2016)
Categ. JCR: NEUROSCIENCES rank: 77 / 258 = 0.298 (2016) - Q2 - T1
Factor impacto SCIMAGO: 1.584 - Clinical Psychology (Q1) - Geriatrics and Gerontology (Q1) - Psychiatry and Mental Health (Q1) - Medicine (miscellaneous) (Q1) - Neuroscience (miscellaneous) (Q2)
Tipo y forma: Article (Published version)
Área (Departamento): Área Anatom.Anatom.Patológ.Com (Dpto. Anatom.,Embri.Genét.Ani.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2020-02-21-13:46:49)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2016-10-19, last modified 2020-02-21